Etiopathogenesis of melasma is multifactorial and remains unclear. Genetic and hormonal factors and exposure to UV radiation are classical influencing factors. There are many other factors that may play a role in the etiology of melasma, such as ingredients in cosmetics, phototoxic and anti-seizure drugs, endocrine disorders (ie, ovarian or thyroid dysfunction), hepatic dysfunction, parasitoses, and nutritional deficiency. It is important to note that most cases of melasma in men and up to one third of cases in women are idiopathic (5).
M elasma is a common, acquired, circumscribed hypermelanosis of the face and occasionally of the neck and forearms, which significantly impacts the quality of life. Chloasma comes from the Greek term for "a green spot" and describes melasma during pregnancy or the "mask of pregnancy".
Although it may affect any race, melasma is much more common in darker-skinned individuals (skin types IV to VI) (1) . There are few prevalence studies on melasma, but there is evidence that the prevalence of this disorder differs among different ethnic groups. Melasma is more common in individuals of Hispanic, Oriental and Asian origin (2) . The reported prevalence of melasma ranges from 8% among Latinas in the United States, to 30% in Southeastern Asian populations. Melasma is more prevalent in women, especially during their reproductive years, with the peak age between 20 and 30 years. It is rarely reported before puberty (3) . Extra-facial melasma is more prevalent in postmenopausal women (4) .
H19 gene on microarray analysis of hyperpigmented and normally pigmented skin in patients with melasma (6) .
Melasma is commonly reported in women using estrogen-progesterone oral contraceptives, hormone replacement therapy for prevention of osteoporosis, and in men using estrogen derivatives for treatment of prostatic cancer (7) . The mechanism of induction of melasma by estrogen may be related to the presence of estrogen receptors on the melanocytes that stimulate cells to produce more melanin (8, 9) . One study of melasma in patients who had never been pregnant or used hormone therapy, reported increased serum concentrations of luteinizing hormone (10) . Sawney and Anand found a high prevalence of chronic pelvic inflammatory disease in women with melasma (11) . These findings may implicate mild ovarian dysfunction as a possible cause of idiopathic melasma.
However, many observations strongly suggest the role of genetic factors. Familial occurrence of melasma has been reported to vary from 20% to 70% in different studies (12) .
Characteristic clinical features of melasma are symmetry of hyperpigmentation and distribution related to trigeminal nerves, which suggest that the neural involvement may play a role in the pathogenesis of pigmentation. Bak et al. found higher levels of neural endopeptidase in melasma lesions and suggest that neuroactive molecules, including nerve growth factor, are critical factors for the pathogenesis of melasma (13) .
It is still unclear why certain areas of the face are predisposed to develop melasma, while others are not. Besides neural factors and hormone receptors, blood vessels may play a role. Human melanocytes may respond to angiogenic factors because normal human melanocytes express functional receptors for vascular endothelial growth factor (VEGF) (14) . In some types of melasma, a pronounced telangiectatic erythema confined to melasma-lesional skin has been observed. Furtermore, increased vascularity is one of the major histologic findings in melasma (15) . These findings may explain the effects of localized microinjection of plasmin inhibitor tranexamic acid, and good therapeutic efficacy of vascular lasers in the treatment of melasma (16) . 
Pathology
Few studies have investigated the histologic alterations in melasma lesions. Compared to uninvolved skin, the areas of hyperpigmentation showed increased deposition of melanin in the epidermis and dermis, as well as enlarged intensely stained melanocytes with prominent dendrites (17) .
Clinical presentation
Clinically, melasma presents as a symmetrically distributed macular pigmentation with irregular borders, which can vary in color ranging from a light to dark brown or brown-gray. The number of hyperpigmented lesions may range from one single lesion to multiple patches located on the forehead, cheeks, dorsum of the nose, upper lip, chin, occasionally on the V-neck area and forearms. Pigmentation may be guttate or confettilike, linear, or confluent; it evolves slowly over weeks or years. The hyperpigmented patches often fade in winter and get worse in the summer.
According to the distribution of lesions, there are three clinical patterns of melasma: centrofacial (65%), malar (20%), and mandibular (15%). The centrofacial pattern involves the forehead, cheeks, upper lip, nose, and chin; the malar pattern involves the cheeks and nose, and mandibular the ramus of the mandible (18) (Figure 1 ).
Wood's lamp (320-400 nm) is used to determine the depth of melanin in the skin. Wood's light may also serve as a prognostic guide in the treatment of melasma, as the epidermal type of melasma is more likely to respond favorably to topical depigmenting agents. Common reasons for diagnostic failure are topical petrolatum and salicylic acid, lint and soap residues since these may fluoresce under Wood's light (19 
Clinical outcome measures
The Melasma Area and Severity Index (MASI) is a common outcome measure, used to assess melasma patients. The severity of melasma in each of the four regions (forehead, right malar region, left malar region and chin) is assessed based on three variables: percentage of the total area involved (A), darkness (D), and homogeneity (H) (22) .
Melasma has a significant negative impact on patients' health related quality of life (QoL), and severely affects social life, emotional well-being, and physical health (23) . Several instruments have been developed to evaluate QoL in melasma patients. Such instruments need to undergo translation, validation and cultural adaptation (24) .
Diagnosis
The diagnosis is clinical and an effort must be made with every patient to detect the individual risk factors and triggers. However, a number of other conditions can mimic melasma (Table 1) .
Therapeutical approaches
The aim of melasma treatment is to eliminate already existing pigmentation and to block de novo pigmentation. Numerous treatment options are currently available for melasma. The choice of treatment options of their combination depends mainly on the type of melasma, effectiveness of prior treatments, and expectations of the patient (25) . New regimens aim to shorten and simplify the treatment. Difficulties in treatment of melasma arise from the following:
1. Melasma is often recalcitrant to treatment 2. High tendency for recurrence/reappearance 3. Risk of adverse events 4. Successful treatment requires long term patient compliance, because therapeutic effects usually become evident after 1-2 months 5. Treatment costs
The basic principles of melasma treatment include: retardation of proliferation of melanocytes, inhibition of melanosome formation, and enhancement of melanosome degradation.
Protection from sun exposure
Melanocytes in melasma are easily stimulated not only by UVB, but also but UVA and visible radiation. In order to maintain good treatment results and to prevent recurrences, one must make major lifestyle changes. Sunbathing is absolutely contraindicated, as a few minutes of sunbathing can reverse the benefit of There are three different categories of bleaching agents: phenolic compounds, non-phenolic compounds, and combination formulas (Table 2) (27) . Some herbal extracts, flavonoids, coumarins and other derivatives are well known hypopigmenting agents (Table 2) . Their classification is difficult, due to a great number of products and various mechanisms of action (28) . In clinical practice, reflectance chromameters measure not only the skin color, and ultraviolet (UV)-induced pigmentation, but the bleaching effect of depigmenting agents.
Hydroquinone (HQ)
Hydroquinone (C6H6O2) is the most commonly used bleaching agent and the gold standard for months of therapy. Sunscreens must be applied daily, during and after the treatment, throughout the sunny months of the year for an indefinite period (18) . Sunscreens are crucial for sun protection, so the use of mineral sunscreens containing titanium dioxide or zinc oxide, with a sun protection factor (SPF) of 30 or higher, is mandatory.
Bleaching agents
Skin lightening or skin bleaching is the practice of using chemical substances in order to lighten the skin color or provide an even toned complexion. Bleaching agents act at various levels of melanin production in the skin, many of which act as competitive tyrosinase inhibitors, the key enzyme in melanogenesis. Others inhibit the maturation of this enzyme or the transport of melanosomes from melanocytes to the surrounding keratinocytes (26) . The most important medical (34) .
Azelaic acid
Azelaic acid (AzA) is a naturally occurring byproduct of the metabolism of Pityrosporum ovale and is associated with hypomelanosis seen in tinea versicolor.
In vitro, azelaic acid reversibly inhibits tyrosinase activity and may also interfere with mitochondrial oxidoreductase activity. Azelaic acid does not appear to affect normal melanocytes, but has an antiproliferative effect on abnormal melanocytes. AzA has antibacterial and anti-keratinizing activities. At 10-20% concentration, twice-daily application may treat melasma with minimal side effects; most patients report a mild but transient irritation of the skin at the beginning of treatment. A recent study suggests that 20% azelaic acid cream applied twice daily may be more effective than hydroquinone 4% in reducing mild melasma (35) .
Kojic acid
Kojic acid is a fungal metabolite that inhibits catecholate activity of tyrosinase, used in a 1-4% cream base, alone or in combination with tretinoin, HQ, and/or corticosteroids. Although kojic acid alone is less effective than HQ 2%, (36) in combination with glycolic acid 10% and HQ 2%, it seems to have a synergistic action (37).
L-ascorbic acid (vitamin C)
Several forms of topical vitamin C are used to treat melasma in 5 to 10% concentrations and can be formulated with other depigmenting agents, such as HQ. Other advantages of vitamin C include antioxidant effects and photo protective properties. The weakness of ascorbic acid is its chemical instability and the hydrophilic nature limits its skin penetration. Magnesium ascorbyl phosphate, ascorbyl palmitate and sodium ascorbyl phosphate are stable derivatives of ascorbic acid. Iontophoresis has been used to promote percutaneous absorption of vitamin C into the skin (38) .
Topical retinoids
Topical retinoids stimulate the cell turnover and promote rapid loss of melanin via epidermopoiesis. Retinoid-induced changes in the stratum corneum melasma treatment. HQ inhibits the conversion of 3,4-dihydroxyphenylalanine (DOPA) to melanin by tyrosinase inhibition, and it also inhibits RNA and DNA synthesis in melanocytic cells, and degrades melanosomes (27) . Since 2001, HQ has been banned in the European Unit (EU) as an ingredient in cosmetics (29) The EU decision was based on its mid-term side effects, mainly exogenous ochronosis and leukoderma-en-confetti (30) . During the past decade, concerns over the safety of HQ have increased. Its use has been connected with toxicity and mutagenicity, and an increased incidence of exogenous ochronosis (31) . Although animal studies demonstrated its toxicity and/or mutagenic effects, these have not been proven in humans (32) . In 2009, the Food and Drug Agency (FDA) renewed its call for additional studies on the safety of HQ. The request for evaluation focuses on uncovering the risks of skin disorders, cancer, and genetic mutations from HQ exposure in humans (33). However, HQ over 2% can only be prescribed from a doctor's office. The effectiveness of HQ is related to the concentration of the preparation, to the vehicle used and the chemical stability of the product. Concentrations of HQ vary from 2% to as high as 10%. Several formulations are commonly prescribed by dermatologists, in order to reach the desired HQ concentration. HQ is easily oxidized, therefore, antioxidants such as 0.1% sodium bisulphate and 0.1% ascorbic acid should be used (34) . The following formula can be prescribed: HQ 3-10% in hydroalcoholic solution (equal parts of propylene glycol and absolute ethanol) or hydrophilic ointment or as a gel containing 10% α-hydroxy acids (AHA) with ascorbic acid 0.1% as preservative. Side-effects of HQ mostly include irritant and rarely allergic contact dermatitis and postinflammatory hyperpigmentation. These side-effects are temporary and they resolve upon discontinuation of HQ. A very rare complication of HQ use is exogenous ochronosis, especially in darker phototypes (34) .
Combination formulas
The skin lightening effects of HQ can be enhanced by adding various topical agents such as tretinoin and corticosteroids (Table 3 ). Tretinoin accelerates cell turnover, and facilitates epidermal penetration of HQ, moreover, it suppresses steroid atrophy, and prevents , Formulation is not preserved by antioxidants, and therefore should never be more that 30 days old; HQ, hydroquinone; ** , The mode of action of N-acetylcystein may be attributed to the intercellular increase of glutathione concentration that stimulates pheomelanin instead of eumelanin synthesis; *** , By lowering the concentration of tretinoin and the use of a non-fluorinated steroid, the aim is to minimize the irritation caused by tretinoin and eliminate local steroid side-effects wavelengths between 630 nm and 1100 nm which are preferentially absorbed by melanin, and pulse duration between 40 ns and 750 ns (43) .
Epidermal melasma can be treated with ablative lasers, such as carbon dioxide (CO2) laser and erbium (Er):YAG laser. Non-ablative 1,550 nm fractional laser therapy has been reported to improve melasma (1).
Q-switched (QS) lasers deliver their energy in nanosecond pulses, hence they selectively target melanosomes. The 1064 nm QS-Nd:YAG is the most widely used laser for melasma. The number of treatments varies from 5 to 10 at 1-week intervals. Encouraging results have been observed in the treatment of the dermal-type melasma by using a novel 694-nm QS ruby fractional laser (44) .
Melasma treatment with pulsed dye laser and the newer antiangiogenic lasers (copper bromide laser) is based on the theory that melasma occurs due to the interaction between cutaneous vasculature and melanocytes. These lasers can be used in patients with melasma and pronounced telengiectasia (45) .
A combination of lasers can be beneficial for dermal melasma. Ablative lasers remove the epidermis; this can be followed by the use of the Q switched pigment selective laser which reaches deeper layers of the dermis (dermal melanophages) without causing serious side effects.
Intense pulsed light
Intense pulsed light (IPL) is a broadband light source that can target a wide range of cutaneous structures, including deeper pigmentation and vasculature (46) .
A study by Figueiredo Souza et al. found that a single session of IPL combined with stable fixed-dose triple combination treatment is a safe and effective treatment for refractory mixed and dermal melasma (47) . A new type of intense pulsed light with pulsein-pulse (PIP) mode (multiple fractionated subpulses in one pulse width), may be a safe and promising treatment for melasma (48) .
New and experimental treatments
Because of escalating concerns about HQ therapy (49), multiple novel agents are being investigated in melasma treatment. Aside from plant extracts, they also include mercury, indomethacin, zinc sulphate (ZnSO4) and newer phenolic derivatives. At present, facilitate the penetration of depigmenting agents in the epidermis, leading to increased depigmentation (39) .
Tretinoin used at 0.05 -0.1% concentrations, applied once nightly, can be effective as monotherapy, but requires 20 to 40-week treatment periods. The most common adverse effects include burning, erythema and scaling. Retinoid dermatitis may itself lead to postinflammatory hyperpigmentation, especially in dark-skinned individuals (40) .
Adapalene 0.1% was found to be a safe and effective monotherapy in the treatment of epidermal melasma with a lower potential for skin-irritation compared to tretinoin (41) .
A study confirms that the efficiency of tretinoin 1% peelings is similar to glycolic acid 70%, with very rare side-effects (42) .
Chemical peels
Superficial chemical peeling agents are beneficial in the management of epidermal melasma and may be used in combination with other forms of melasma treatment. The peel solution is selected according to patient's needs, skin type and sensitivities. Because of their superficial action, superficial peels can be used in nearly all skin types (1) .
Medium-depth peels may be an alternative treatment in refractory cases of severe melasma. All types of chemical peels, but mainly alpha-hydroxy acids, beta-hydroxy acid, salicylic acid, Jessner's original and modified solutions, and trichloroacetic acid are used alone or in combination with other depigmenting agents. It has to be emphasized that the response of melasma to chemical peels is rather unpredictable and there is a tendency for changes in pigmentation after chemical peel, especially in dark skinned individuals. Chemical peeling remains as an alternative modality for patients with melasma (34).
Laser and light therapies
Based on actual evidence, laser and light therapies show the best response in light-skinned patients, and are considered as third-line agents. Post inflammatory hyperpigmentation remains the most important side effect. Recurrences are common and are seen in up to 50% (1) .
Melanosomes are the primary target of the laser-induced damage, and melanin is the main chromophore. Therefore it is important to choose Table 4 shows melasma therapies, and level of evidence according to Rendon et al. (52) .
Conclusion
At present, there is no universally effective treatment for melasma. The mainstay of treatment is use of there are no controlled studies investigating the efficacy and safety of these compounds. Although preliminary data showed beneficial effects of zinc for melasma, a recent study confirmed that topical zinc therapy is not highly effective in reducing the severity of melasma (50) . In recent years, the skin whitening industry has used complex mixtures of ingredients that target different mechanisms like tyrosinase expression, transfer of melanosomes, antioxidant and anti-inflammatory effects. Different commercially available whitening products contain various natural (glutathione; leukocyte extracts), particularly herbal ingredients, although information on some formulations are not always clear (51): Paper mulberry (Broussonetia sunscreens along with topical medications that suppress melanogenesis. Topical hydroquinone alone or in stable fixed-dose triple combination topical therapy is the first line of treatment; chemical peels are considered second-line therapy for refractory cases, and laser and light are considered the third-line treatment. Nowadays, there are no controlled studies investigating the efficacy and safety of multiple novel and experimental agents.
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Novi aspekti melazme
Sažetak južnoistočnjačke azijske populacije. Melazma ima veću
